Aprecia Pharmaceuticals LLC

Aprecia Pharmaceuticals Company

Therics, Inc.

Thomas George West

Henry Leon Surprenant

Thomas J Bradbury

Jaedeok Yoo

Jules S Jacob

James Iskra

Thomas J Bebb

Donald C Monkhouse

Nemichand B Jain

Norman Coyle

Kelly E Caputo

Qing Wen Liu

Mahendra R Patel

Kenneth J Sultzbaugh

Aleece M Phillips

Micael Guillot

Jules Jacob

Peter A Materna

Christopher M Gaylo

Alfred Anthony Litwak

Amit S Patel

Sunil Saini

Lauren Beach

Chen-Chao Wang

Timothy J Pryor

Kathleen D Chesmel

William R Gross

Jennifer Patterson

Henry L Surprenant

Lauren E Beach-Herrera

Munhee Lee

Jae D Yoo

Matthew F Boldt

Timothy S Tracy

Henry Cabral

Jonathan McGlohorn

Mahesh Krishnan

Heather Ann Beam

Kelly Caputo

A rapidly-orodispersible dosage form comprising a porous, bound-powder matrix and one or more internal cavities is provided, as well as three-dimensional printing methods for making the same. Each internal cavity is configured to contain one or more payloads, particularly pharmaceutical medicaments, while isolating the payloads from the external environment outside of the dosage form. Each payload can be contained within its cavity in its native form without having to be combined with the bound-powder matrix or binding liquid. Dosage forms can disintegrate in water or saliva in less than two minutes, independently of the payload(s) or medicament(s) contained within. The dosage forms can be formed as unitary tablets, or as two-piece tablets comprising a container body and a lidding body that are secured together to isolate the one or more cavities and their payloads inside.

Rapidly-orodispersible tablets having an interior cavity

A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.

Rapid disperse dosage form

A three-dimensional printing system and equipment assembly for the manufacture of three-dimensionally printed articles is provided. The equipment assembly includes a three-dimensional printing build system, an optional liquid removal system and an optional harvester system. The build system includes a conveyor, plural build modules and at least one build station having a powder-layering system and a printing system. The equipment assembly can be used to manufacture pharmaceutical, medical, and non-pharmaceutical/non-medical objects. It can be used to prepare single or multiple articles.

Three-dimensional printing system and equipment assembly

Rapidly-orodispersible tablets having an in interior cavity

A method and system of forming a pharmaceutical dosage form within a portion of a blister packaging. The method includes the steps of providing a blister packaging for the dosage form with depressions. A predetermined amount of a drug-containing powder material comprising drug-containing particles is deposited into a substantially uniform powder layer within the depressions. A binding liquid is then deposited in a pattern on the powder layer within the depressions, to bind the particles of the powder layer and form an incremental wetted layer. Excess solvent in the binding material can be removed to form an incremental bound layer. These steps are repeated in sequence at least one or more times to form the pharmaceutical dosage form within the blister packaging.

Method and system for forming a dosage form within a packaging

A taste-masked rapidly dispersible dosage form of topiramate is provided. Wax coated particles of topiramate are included within a porous bound matrix. The topiramate retains its taste-masked form after dispersion in the mouth of a subject even though the particles are not coated with a polymeric material. The dosage form disperses in saliva or water in less than 2 min even though it has a high content of wax. It can be used to treat diseases or disorders that are therapeutically responsive to topiramate or a derivative thereof.

Rapidly dispersible dosage form of topiramate

A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.

Rapidly dispersible dosage form of oxcarbazepine

A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.

Rapid disperse dosage form containing levetiracetam

Growing community of inventors

Lawrenceville, NJ, United States of America

Thomas George West